Cargando…
Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial
BACKGROUND: Chronic liver scarring from any cause leads to cirrhosis, portal hypertension, and a progressive decline in renal blood flow and renal function. Extreme renal vasoconstriction characterizes hepatorenal syndrome, a functional and potentially reversible form of acute kidney injury in patie...
Autores principales: | Snowdon, Victoria K., Lachlan, Neil J., Hoy, Anna M., Hadoke, Patrick W. F., Semple, Scott I., Patel, Dilip, Mungall, Will, Kendall, Timothy J., Thomson, Adrian, Lennen, Ross J., Jansen, Maurits A., Moran, Carmel M., Pellicoro, Antonella, Ramachandran, Prakash, Shaw, Isaac, Aucott, Rebecca L., Severin, Thomas, Saini, Rajnish, Pak, Judy, Yates, Denise, Dongre, Neelesh, Duffield, Jeremy S., Webb, David J., Iredale, John P., Hayes, Peter C., Fallowfield, Jonathan A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5330452/ https://www.ncbi.nlm.nih.gov/pubmed/28245243 http://dx.doi.org/10.1371/journal.pmed.1002248 |
Ejemplares similares
-
A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP)
por: Gifford, Fiona J., et al.
Publicado: (2020) -
Reversibility of liver fibrosis
por: Pellicoro, Antonella, et al.
Publicado: (2012) -
Disconnect between the effects of serelaxin on renal function and outcome in acute heart failure
por: Beldhuis, I. E., et al.
Publicado: (2023) -
Non-invasive assessment of liver disease in rats using multiparametric magnetic resonance imaging: a feasibility study
por: Hoy, Anna M., et al.
Publicado: (2018) -
Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial
por: Corcoran, David, et al.
Publicado: (2020)